Shankho Ganguli, MD
Interventional Cardiology · Paducah, KYNPI 1407122989
Payments from drug & device makers
What this record shows
This record is dominated by grants: $43,155 of the $56,321 with a category attached, or 76.6%. 23 manufacturers reported payments, led by Boston Scientific at 48.0% of the total. Reporting peaked in 2019 at $44,558 and has fallen 97.4% since, to $1,159 in 2025.
Across 254 payments — averaging $221.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$27K
- Medtronic$24K
- Edwards Lifesciences$2K
- Abbott$1K
- Novartis$542
- Amgen$287
- plus $2K from 17 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Grants$43,15577%
- Travel & lodging$5,36710%
- Food & beverage$7,79814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $27,037 |
| Medtronic(2 entities) | 66 | $23,563 |
| Edwards Lifesciences | 18 | $2,378 |
| Abbott | 17 | $1,007 |
| Novartis | 36 | $542 |
| Amgen | 21 | $287 |
| Abiomed | 6 | $260 |
| Pfizer | 13 | $247 |
| Boehringer Ingelheim | 8 | $140 |
| E.r. Squibb & Sons, L.L.C. | 6 | $137 |
| Merck | 8 | $121 |
| Philips North America LLC | 8 | $121 |
| Actelion Pharmaceuticals US, Inc. | 9 | $112 |
| Johnson & Johnson | 6 | $110 |
| Irhythm Technologies, Inc. | 2 | $52 |
| Daiichi Sankyo Inc. | 2 | $47 |
| AstraZeneca | 3 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $32 |
| Avinger Inc. | 1 | $24 |
| Shockwave Medical, Inc | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STENTS$25,000
- CoreValve Evolut$20,017
- Watchman$1,555
- COREVALVE EVOLUT R$1,064
- HawkOne$886
- Edwards SAPIEN 3 Transcatheter Heart Valve$442
- Xience V coronary stent system$322
- Farapulse$188
- MitraClip System$172
- PORTICO$146
- SAPIEN 3 Ultra RESILIA$139
- Impella$118
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$102
- MitraClip$100
How this compares
$56,321 in reported general payments places this provider in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 209 | $221,401 |
| EntrestoSacubitril/Valsartan | 150 | $147,753 |
| JardianceEmpagliflozin | 52 | $52,902 |
| XareltoRivaroxaban | 43 | $48,138 |
| FarxigaDapagliflozin Propanediol | 44 | $35,686 |
| Repatha SureclickEvolocumab | 31 | $23,943 |
| WegovySemaglutide | 13 | $17,024 |
| BrilintaTicagrelor | 29 | $15,852 |
| Repatha SyringeEvolocumab | 24 | $10,437 |
| Amiodarone Hcl | 60 | $4,748 |
| Clonidine | 29 | $3,476 |
| Ranolazine ErRanolazine | 26 | $3,100 |
| Atorvastatin Calcium | 253 | $2,673 |
| Midodrine Hcl | 44 | $2,301 |
| Metoprolol Succinate | 135 | $1,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $247 | $221,401209 claims |
| NovartisEntresto | $542 | $147,753150 claims |
| Boehringer IngelheimJardiance | $140 | $52,90252 claims |
| AstraZenecaFarxiga, Brilinta | $39 | $51,53873 claims |
| Johnson & JohnsonXarelto | $110 | $48,13843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Paducah
- James FordPaducah$67K
- Martin RainsPaducah$45K
- Timothy McDermottPaducah$17K
- Michael FaulknerPaducah$13K
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.